Vacinas COVID-19 e reações imunoalérgicas
COVID-19 vaccines and immunoallergic reactions
Fátima Rodrigues Fernandes; Ana Karolina B. Berselli Marinho; Mônica de Araújo Álvares da Silva; Claudia Leiko Yonekura Anagusko; Adriana Azoubel Antunes; Cláudia França Cavalcante Valente; Irma C. Douglas Barreto; Lorena de Castro Diniz; Alexandra S. Watanabe; Renata Rodrigues Cocco; Marcelo Vívolo Aun; Pedro Giavina-Bianchi; Ekaterini Simões Goudouris; Dirceu Solé; Flávio Sano
Resumo
A avaliação dos riscos e benefícios deve ser realizada para qualquer intervenção preventiva, diagnóstica ou terapêutica em Medicina. As vacinas, assim como qualquer imunobiológico, são consagradas pelas inúmeras vantagens inerentes à proteção da saúde, apesar dos potenciais riscos de eventos adversos que, na imensa maioria das vezes, são raros, leves e controláveis. O desenvolvimento de vacinas contra o novo SARS-CoV-2 representa um dos principais anseios da população mundial e representa extraordinário avanço da Ciência. Pacientes com histórico de alergias graves a algum componente das vacinas ou a uma dose prévia de alguma delas, devem ser avaliados com cautela pelo especialista para decidir se esta deverá ser contraindicada, aplicada com supervisão médica, ou se estará indicado protocolo de dessensibilização.
Palavras-chave
Abstract
The assessment of risks and benefits must be carried out for any preventive, diagnostic, or therapeutic intervention in medicine. Vaccines, like any biologic, are recognized for the innumerable advantages in public health, despite the potential risks of adverse events that, in the vast majority of cases, are rare, mild, and controllable. The development of vaccines against the new SARSCoV-2 represents one of the main wishes of the world population as well as an extraordinary advance in science. Patients with a history of severe allergies to any component of the vaccines or reaction to a previous dose of any of them should be carefully evaluated by the specialist to decide whether vaccination should be contraindicated or administered with medical supervision, or if a desensitization protocol will be indicated.
Keywords
References
1. Aps LRMM, Piantola MAF, Pereira SA, Castro JT, Santos FAO, Ferreira LCS. Eventos adversos de vacinas e as consequências da não vacinação: uma análise crítica. Rev Saude Pública. 2018;52:40.
2. McNeil MM, Frank DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463‑72.
3. Guia de Imunização SBIm/ASBAI – Asma, Alergia e Imunodeficiências 2020-2021 [Internet]. Disponível em: https://asbai.org.br/wpcontent/uploads/2020/10/Guia-Imunizac%cc%a7o%cc%83esASBAI_SBIm-2020-versa%cc%83o-final.pdf
4. Giavina-Bianchi P, Kalil J. Polyethylene Glycol Is a Cause of IgE-Mediated Anaphylaxis. J Allergy Clin Immunol Pract. 2019;7:1874-5.
5. Yang Q, Jacobs TM, McCallen JD, Moore DT, Huckaby JT, Edelstein JN, et al. Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population. Anal Chem. 2016; 88(23):11804‑12. https://doi.org/10.1021/acs.analchem.6b03437.
6. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20:615-20.
7. Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, HavenarDaughton C, et al. A perspective on potential antibody-dependent enhancement of SARS CoV2. Nature. 2020;584:353‑63.
8. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNABased Covid-19 Vaccine Candidates. N Engl J Med. 2020 Oct 14:NEJMoa2027906.
9. Polack FP, Thomas SJ, Kitchin N, Absalon J. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020. doi: 10.1056/NEJMoa2034577 .
10. Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine [Internet]. Disponível em: https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontechvaccine-for-covid-19/information-for-healthcare-professionals-onpfizerbiontech-covid-19-vaccine. Acessado em: 10/12/2020.
11. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2020; published online Dec 8. https://dx.doi.org/10.1016/S0140-6736(20)32661-1.
Submitted date:
12/19/2020
Accepted date:
12/20/2020
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email